Eponyms in Oncology: Bence-Jones Protein
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of the Bence-Jones protein.
Multiple Myeloma
Frontline Daratumumab Improves Progression-Free Survival in High-Risk Multiple Myeloma
The addition of daratumumab resulted in a 41% reduction in the risk of disease progression or death.
Elotuzumab Does Not Improve PFS in Newly Diagnosed Multiple Myeloma
Adding elotuzumab to lenalidomide and dexamethasone did not improve any efficacy outcomes.
Risk of Neurologic AEs Lower With Immune Checkpoint Inhibitors Than With Other Cancer Therapies
The risk of neurologic adverse events was 41% lower in patients treated with immune checkpoint inhibitors than in patients who received another drug regimen or a placebo.
Lenalidomide Maintenance Superior to Bortezomib for Myeloma Patients With Abn1q
Among patients with Abn1q, those who received bortezomib-based maintenance had significantly worse progression-free survival and overall survival.
Racial Disparities Noted in Treatment With Bone-Modifying Agents Among Patients With Multiple Myeloma
Researchers sought to determine if there are racial disparities in treatment with bone-modifying agents for patients with multiple myeloma.
Real-World Data Confirm Lack of Standard Care for Triple-Exposed Multiple Myeloma
After triple-class exposure, patients received more than 50 unique treatment regimens.
Most Blood Cancer Drug Trials Are Not Randomized, Use Surrogate Endpoints
Of more than 2500 trials analyzed, 21% were randomized.
Predictors of Mortality During Hospital Stays in Patients With Multiple Myeloma
Researchers sought to determine the predictors of mortality during hospital stays in patients with multiple myeloma.
Cancer Risks, Mortality Vary With CKD Stage
The proportion of patients with chronic kidney disease who die from cancer may be underappreciated.
- Loading...
Loading...
Next post in General Oncology
Loading... 
Loading...